Serbentų vaistinė - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 936,312 | 1,128,026 | 997,527 | 739,942 | 586,756 | 615,396 | 655,875 | 822,495 |
| Profit before tax | 120,906 | 114,251 | 43,413 | 69,338 | 8,492 | 42,321 | -4,382 | -2,017 |
| Net profit | 104,115 | 95,299 | 32,595 | 60,849 | 7,406 | 39,318 | -4,382 | -2,017 |
| Equity | 266,033 | 161,332 | 123,927 | 114,776 | 72,182 | 86,499 | 82,117 | 80,100 |
| Liabilities | 31,074 | 157,992 | 96,037 | 41,190 | 82,235 | 16,188 | 4,287 | 71,491 |
| Non-current assets | 8,333 | 4,277 | 2,255 | 2,359 | 1,654 | 2,045 | 1,509 | 1,196 |
| Current assets | 288,774 | 315,047 | 217,709 | 153,607 | 152,763 | 100,642 | 84,895 | 150,395 |
| Total assets | 297,107 | 319,324 | 219,964 | 155,966 | 154,417 | 102,687 | 86,404 | 151,591 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 16,444 | 9,287 | 7,023 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +4.9% | +20.5% | -11.6% | -25.8% | -20.7% | +4.9% | +6.6% | +25.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 35.0% | 29.8% | 14.8% | 39.0% | 4.8% | 38.3% | -5.1% | -1.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 39.1% | 59.1% | 26.3% | 53.0% | 10.3% | 45.5% | -5.3% | -2.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 11.1% | 8.4% | 3.3% | 8.2% | 1.3% | 6.4% | -0.7% | -0.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 12.9% | 10.1% | 4.4% | 9.4% | 1.4% | 6.9% | -0.7% | -0.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 1.0 | 0.8 | 0.4 | 1.1 | 0.2 | 0.1 | 0.9 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 312,104 | 376,009 | 332,509 | 246,647 | 195,585 | 205,132 | 218,625 | 274,165 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Serbentų vaistinė - Social security debts
The company had no debts to Sodra
Serbentų vaistinė - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Serbentu vaistine, UAB (code 302300049) is a Private Limited Liability Company engaged in retail sale of pharmaceutical products. In 2025, the company generated revenue of €822.5K, up 25.4% year on year and 33.6% over two years. Despite stronger sales, profitability remained weak: net profit was -€2.0K in 2025, after a loss of -€4.4K in 2024, compared with a profit of €39.3K in 2023. The 2025 profit margin was -0.2%, indicating that revenue growth did not translate into earnings. The balance sheet expanded notably in 2025, with total assets rising to €151.6K from €86.4K in 2024, mainly through short-term assets of €150.4K. Equity stood at €80.1K and liabilities at €71.5K, giving a debt-to-equity ratio of 0.89 and an equity ratio of 52.8%. Efficiency metrics were mixed, with asset turnover at 5.43x, ROA at -1.3%, and ROE at -2.5%. Revenue per employee was €274.2K, while profit per employee was -€672.